Hsbc Holdings PLC Acquires Shares of 127,125 United Therapeutics Corporation $UTHR

Hsbc Holdings PLC acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 127,125 shares of the biotechnology company’s stock, valued at approximately $68,899,000. Hsbc Holdings PLC owned approximately 0.30% of United Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Canada Pension Plan Investment Board bought a new position in shares of United Therapeutics during the second quarter worth about $3,359,000. Nicholas Investment Partners LP bought a new stake in United Therapeutics in the second quarter valued at about $3,869,000. Legal & General Group Plc acquired a new stake in United Therapeutics during the second quarter valued at approximately $112,209,000. The Manufacturers Life Insurance Company acquired a new stake in United Therapeutics during the second quarter valued at approximately $22,486,000. Finally, Fiduciary Financial Advisors bought a new position in United Therapeutics during the 2nd quarter worth approximately $30,000. Institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $511.97, for a total value of $4,863,715.00. Following the sale, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $166,105,082.71. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total transaction of $4,342,062.00. Following the transaction, the executive vice president directly owned 45,172 shares of the company’s stock, valued at approximately $23,631,280.08. This trade represents a 15.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 424,075 shares of company stock worth $227,683,710 over the last ninety days. 8.60% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on UTHR shares. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Bank of America reduced their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. JPMorgan Chase & Co. lifted their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a report on Thursday, August 6th. Finally, Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $646.00.

United Therapeutics Trading Down 0.4%

Shares of United Therapeutics stock opened at $516.68 on Thursday. The business’s 50 day simple moving average is $531.06 and its 200-day simple moving average is $538.56. The stock has a market capitalization of $22.16 billion, a price-to-earnings ratio of 18.49, a PEG ratio of 1.76 and a beta of 0.59. United Therapeutics Corporation has a twelve month low of $302.19 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same quarter last year, the business posted $6.41 EPS. The business’s revenue was down 1.9% on a year-over-year basis. Sell-side analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.